|
|
Spotlight on Prof. Akiva Mintz, MD, Ph.D, – Columbia University |
|
|
Prof. Akiva Mintz, M.D., Ph.D., is a physician-scientist whose translational research focuses on developing cancer therapies with non-invasive molecular imaging. Dr. Mintz is professor of radiology at Columbia University Irving Medical Center (CUIMC) and attending radiologist at NewYork-Presbyterian Hospital.
In this interview. Dr. Mintz highlights the capabilities of MILabs’ CT-guided 3D optical imaging for hard-to-reach tumors, such as brain cancer. He further illustrates the excellent correlation of 3D OI/CT with 68Ga and 89Zr PET-based approaches. Read the full interview here.
|
|
No one will see it like you |
|
|
As illustrated by Dr. Mintz in his recent articles, preclinical 3D OI/CT can be used as a valuable alternative to translational nuclear imaging. However, there is more than meets the eye:
- SPECT images at 120 microns,
- PET at 0.6 mm; some even without positron-range blurring
- Alpha and beta theranostics at 0.75 mm, without surrogates
- Bioluminescence & fluorescence in 3D dimensions,
- CT with industry-leading low dose and voxels down to 2.4µm
- Simultaneous PET/PET and PET/SPECT imaging in one shot.
MILabs VECTor: no one will see as much and as clear as you. For more information: click here
|
|
Avoiding the “valley of death” |
|
|
In a recent article, the team of Columbia University, explains how to avoid the valley of death – the demise of novel therapeutics before reaching commercialization and clinical implementation. More specifically, Dr. Mintz comments on the use of CT-guided 3D Optical imaging along the preclinical translational spectrum, and the ability to correlate Optical tomography with human translational PET and SPECT techniques. For further reading, click here and here.
|
|
Accelerating high-energy theranostics into the clinic |
|
|
Researchers at Fudan University, Shanghai, Chinadeveloped 131I-DOX-loaded microbeads for targeted radiotherapy to avoid recurrence of tumors. Contrary to microbeads labeled with 131I or loading DOX alone, they attributed the favorable nanoparticle characteristics to the sensitization of DOX to 131I-induced ionizing DNA radiation damage under hypoxia by embolization. They feel that their novel method shows great potential for clinical translation. For further reading, click here.
|
|
High-resolution bone and vasculature imaging |
|
|
To further underscore the versatility of MILabs VECTor CT, we illustrate here the outstanding performance of its fully integrated low-dose in-vivo CT system for bone disease imaging and angiography (CTA). In addition to optical and nuclear imaging, the VECTor X-ray CT system can at low doses, visualize blood flow in arterial vessels throughout the body, from arteries serving the brain to those bringing blood to the lungs, heart, kidneys, arms, arteries and bones. For further reading, click here.
|
|
When ORS 2021 calls for advanced applications: |
|
|
We did respond with an advanced webinar to highlight our participation in the virtual Orthopaedic Research Society (ORS) meeting of February 12-16, 2021.
Dr. Behdad Pouran will talk about musculoskeletal imaging, and present examples of advanced imaging techniques performed on MILabs’ VECTor system. The webinar will cover in vivo and ex vivo bone, bone-implant and soft tissue imaging. It should be of interest to specialists in the fields of orthopedics, maxillofacial, cardiovascular, neurology, pulmonary and oncology. Please click here for the presentation.
|
|
MILabs Preclinical Imaging Solutions |
|
|
Job Openings to support MILabs’ accelerating growth |
|
|
With a compounded annual growth rate of nearly 50% since 2018, MILabs seeks talented individuals to further scale-up its organization and to strengthen the support of its customers and industry collaborators.
We are searching for:
- Sales & Business Director North America at MILabs
- Field Service Engineer North America at MILabs
|
|
|
|
|
|
|
|